A chemical investigation of Ypsilandra thibetica led to the isolation of ten previously undescribed homo-aro-cholestane glycosides, aroypsilandrosides A–J ( 1 − 10 ), along with the known analogue 11 and its aglycone 12 . Their structures and absolute configurations were elucidated by extensive spectroscopic analysis, chemical methods, and single-crystal X-ray diffraction. Notably, aroypsilandroside A ( 1 ) is an unprecedented B- abeo -homo-aro-cholestane glycoside featuring a 6/5/6/5/6 fused ring system. Aroypsilandrosides B–D ( 2 – 4 ) possess a rare Δ 4 double bond with a hydroxyl or carbonyl group at C-6, whereas aroypsilandrosides H–J ( 8 – 10 ) represent the second report of naturally occurring homo-aro-cholestane glycosides bearing a carboxylated aromatic E-ring. Compounds 1 – 8 , 11 , and 12 were evaluated for their effects on the ex vivo expansion of human cord blood (CB) CD34 + hematopoietic stem and progenitor cells (HSPCs). Compound 11 markedly expanded hematopoietic stem cells (HSCs, 7.6-fold) and multipotent progenitors (MPPs, 29.2-fold), representing the most potent HSC and MPP expansion activity reported to date among naturally occurring compounds in this assay. Furthermore, structure-activity relationship analysis identified the bidesmosidic homo-aro-cholest-5-ene glycoside skeleton as a new chemotype for HSPC expansion. These findings establish homo-aro-cholestane glycosides as a promising class of modulators for ex vivo expansion of human CB HSPCs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: